ASND (Ascendis Pharma A/S Ordinary Share)
Insider Trading Activity
Every open-market purchase and sale reported by ASND officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | LARS HOLTUG | Director | Sell | — | — |
| 2026-08-18 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| 2026-06-02 | SCOTT THOMAS SMITH | EVP & Chief Financial Officer | Buy | — | — |
| 2026-06-01 | SCOTT THOMAS SMITH | EVP & Chief Financial Officer | Buy | — | — |
| 2026-06-01 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| 2026-05-27 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| 2026-05-12 | FLEMMING STEEN JENSEN | See Remarks | Sell | — | — |
| 2019-09-03 | Adrian Rawcliffe | CEO and CFO | A | — | — |
| 2019-08-07 | Rafael Amado | President, R&D | Sell | — | — |
| 2019-08-05 | John Lunger | Chief Patient Supply Officer | A | — | — |
| 2019-07-03 | Barbara Gayle Duncan | Director | A | — | — |
| 2019-07-03 | Ali Behbahani | Director | A | — | — |
| 2019-07-03 | Lawrence M Alleva | Director | A | — | — |
| 2019-07-03 | Tal Zvi Zaks | Director | A | — | — |
| 2019-07-03 | DAVID M MOTT | Director | A | — | — |
| 2019-07-03 | Giles Francis Bertram Kerr | Director | A | — | — |
| 2019-07-03 | John Furey | Director | A | — | — |
| 2019-07-03 | Charles Elliott Sigal | Director | A | — | — |
| 2019-06-27 | Adrian Rawcliffe | Chief Financial Officer | A | — | — |
| 2019-05-17 | James Noble | Chief Executive Officer | M | — | — |
| 2019-01-16 | Rafael Amado | President, R & D | Sell | — | — |
| 2019-01-16 | William C Bertrand JR | Chief Operating Officer | Sell | — | — |
| 2019-01-16 | Adrian Rawcliffe | Chief Financial Officer | Sell | — | — |
| 2019-01-16 | Gwendolyn Knowlton Binder-Scholl | Chief Technology Officer | Sell | — | — |
| 2019-01-08 | James Noble | Chief Executive Officer | A | — | — |
| 2019-01-08 | HELEN KATRINA TAYTON-MARTIN | Chief Business Officer | A | — | — |
| 2019-01-08 | William C Bertrand JR | Chief Operating Officer | A | — | — |
| 2019-01-08 | Rafael Amado | President, R & D | A | — | — |
| 2019-01-08 | Adrian Rawcliffe | Chief Financial Officer | A | — | — |
| 2018-12-19 | Lawrence M Alleva | Director | Buy | — | — |
| 2018-10-02 | Gwendolyn Knowlton Binder-Scholl | Chief Technology Officer | Sell | — | — |
| 2018-09-10 | Anthony A. Florence Jr. | 10%+ Owner | Buy | — | — |
| 2018-09-10 | Ali Behbahani | Director | Buy | — | — |
| 2018-09-10 | FOREST BASKETT | 10%+ Owner | Buy | — | — |
| 2018-09-10 | NEA 14 GP, LTD | 10%+ Owner | Buy | — | — |
| 2018-09-10 | PETER J BARRIS | 10%+ Owner | Buy | — | — |
| 2018-09-10 | Ravi Viswanathan | 10%+ Owner | Buy | — | — |
| 2018-09-10 | SCOTT D SANDELL | 10%+ Owner | Buy | — | — |
| 2018-09-10 | DAVID M MOTT | Director | Buy | — | — |
| 2018-09-10 | PATRICK J KERINS | 10%+ Owner | Buy | — | — |
| 2018-09-10 | Peter W. Sonsini | 10%+ Owner | Buy | — | — |
| 2018-09-10 | M JAMES BARRETT | 10%+ Owner | Buy | — | — |
| 2018-08-31 | Gwendolyn Knowlton Binder-Scholl | Chief Technology Officer | Sell | — | — |
| 2018-08-07 | Rafael Amado | President, R & D | A | — | — |
| 2018-06-26 | Charles Elliott Sigal | Director | A | — | — |
| 2018-06-26 | Giles Francis Bertram Kerr | Director | A | — | — |
| 2018-06-26 | Ali Behbahani | Director | A | — | — |
| 2018-06-26 | Lawrence M Alleva | Director | A | — | — |
| 2018-06-26 | Tal Zvi Zaks | Director | A | — | — |
| 2018-06-26 | DAVID M MOTT | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | EVP & Chief Financial Officer | 4,367 | — |
| — | Director | 4,000 | — |
| — | Director | 2,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ASND quote page; the site-wide leaderboard is on the insider transactions hub.